PACB Pacific Biosciences of California Inc.

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time.

The call will be webcast and may be accessed at PacBio’s website at .

Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)

Listen live via internet or replay: Toll-free: 1-888-349-0136

International: 1-412-317-0459

If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q3 Earnings Call.”

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:

Jim Gibson

Media:



EN
22/10/2025

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.12
DHR DANAHER CORPORA...
ILMN ILLUMINA INC. ... (+17)

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

DHR DANAHER CORPORATION
ILMN ILLUMINA INC.
WAT WATERS CORPORATION
TECH BIO-TECHNE CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
A AGILENT TECHNOLOGIES INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
PKI PERKINELMER INC.
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
AVTR AVANTOR INC.
PSNL PERSONALIS
TWST TWIST BIOSCIENCE
PGEN PRECIGEN INC
OGEN ORAGENICS INC.
9h / 23m 9h / 23m 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2...

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the ca...

October 22, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Major Advances for Revio and Vega to Lower Genome Cos...

PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chem...

October 14, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio HiFi Technology Selected as Core Platform for South Korea’s Nat...

PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, a landmark national initiative led by the Korea Disease Co...

October 13, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic a...

Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to date MENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic data from as...

October 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch